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Recent advances in rheumatology have contributed 
to elucidate the complex pathogenic processes 
that underlie the development and progression of 
rheumatic diseases. This has led to the advent of 
new therapies to treat these conditions, including 
the biologic therapies. The use of synthetic disease-modifying 
anti-rheumatic drugs (DMARDs) together with biologic therapies 
has increased dramatically across a range of diseases, and resulted 
in improved outcomes for patients. In a study done in Spain, 
the overall age-standardised mortality rate for systemic lupus 
erythematosus (SLE) increased during 1981 - 1999 and stabilised 
during 2000 - 2010.[1] The mean age at death increased with time, 
from 42 years in 1981 to 61 years in 2010.[1] Similar mortality trends 
have been observed in patients with rheumatoid arthritis (RA), 
even though mortality still remains higher in RA patients compared 
with the general population.[2] The overall SLE survival rates have 
increased significantly between the 1950s and 2000s, from 74.8% 
to 94.8% and 63.2% to 91.4% for the overall 5-year and 10-year 
survival, respectively.[3] These improved outcomes are thought to 
be due to a combination of earlier recognition of mild disease and 
better approaches to therapy.
The European League Against Rheumatism (EULAR) and the 
American College of Rheumatology (ACR) have recently joined 
forces and contributed significantly to improved outcomes in 
rheumatic diseases by revising the classification criteria for most 
of these diseases, with the new criteria having higher sensitivity 
and specificity, which contribute to an early diagnosis. The latest 
contribution was the 2015 ACR/EULAR classification criteria 
for gout.[4] Diagnostic imaging with magnetic resonance imaging 
(MRI) and ultrasonography has provided a new perspective to the 
management of arthritis, revealing subclinical inflammation and 
predicting progression of joint damage – thus contributing to early 
detection.[5] Therefore, much more can be done for patients before the 
development of irreversible damage. 
However, despite this improvement in outcomes, musculoskeletal 
(MSK) disorders still rank highest in prevalence as the cause of 
chronic ill-health, long-term disability, and consultation with 
healthcare professionals, as was shown in the Burden of Global 
Disease 2010 study.[6] This is against the background of MSK 
disorders contributing only 3.4% and 1.7% of the total disease 
burden in the developed and developing world, respectively.[6] 
Osteoarthritis and low back pain remain the largest contributors 
to the global disability burden.[6] The Bone and Joint Decade 2000 - 
2010, endorsed by many organisations including the World Health 
Organization (WHO) and many governments, has acknowledged 
the rising burden of MSK disorders.[7] In 2013, the Global Burden 
of Disease (GBD) study showed that the proportion of disability-
adjusted life-years (DALYs) caused by years lost due to disability 
(YLD) increased globally from 21.1% in 1990 to 31.2% in 2013.[8] 
Furthermore, the burden of MSK disorders in terms of DALYs 
in the developing world (21  076  000 DALYs) is estimated to be 
almost 2.5 times that in the developed world (8 723 000 DALYs).[6] 
For SLE, survival rates in developing countries are significantly 
lower than those reported in developed countries such as the 
USA, Western Europe and Canada, where 5- and 10-year survival 
rates surpass 90%.[9] In South Africa (SA), the 5-year survival 
rate was shown to be between 57% and 72% (1986 - 2003) in a 
case series of 226 SLE patients.[9] These studies show that MSK 
disorders are the largest contributors to disability and chronic 
ill-health, and further indicate the wide gap between developing 
and developed countries. 
Developing countries are faced with several challenges in 
relation to reducing the burden of MSK disorders. In Africa, 
rheumatology as a specialty is considerably neglected and 
under-funded. It has to compete for scarce resources, which are 
allocated to communicable diseases such as tuberculosis, HIV 
and malaria, all of which are life threatening compared with the 
causes of disability. A systematic review carried out to address 
the prevalence of arthritis in Africa identified the paucity 
of prevalence data in Africa.[10] Funding for rheumatology-
related research is inadequate and, in addition, the ratio of 
rheumatologists to population is high, in one study ranging 
from 1:35  000 to 1:1  600  000.[9] Training of rheumatologists is 
insufficient and there is difficulty accessing them; this leads 
to delays in appropriate treatment and further contributes to 
disability, as the window of opportunity to start treatment has 
been missed. In SA, some provinces, such as Limpopo, do not 
have rheumatologists and some, such as the Eastern Cape, have one 
rheumatologist serving the entire population of about 6.9 million.[11] In 
developed countries, nurses are trained to deal with MSK disorders; 
they are key in managing these disorders. One other challenge 
is that of limited medication options due to unaffordability and/
or unavailability.
The major contributor to the GBD is the increase in the ageing 
population. As people become older, their likelihood of suffering 
from MSK disorders increases and quality of life deteriorates. To 
improve outcomes for MSK disorders in developing countries, 
there needs to be a change in emphasis, so that larger resources 
are allocated to non-communicable diseases. Medical schools 
have to introduce students to the diagnosis and treatment of MSK 
disorders early, general physicians and other specialists need to 
have greater exposure to these conditions and primary care workers 
should be trained to manage these disorders early with DMARD 
therapy. Resources should be allocated for the training of more 
rheumatologists and, more importantly, rheumatology nurses. 
CME could play a vital role in the dissemination of information to 
practitioners. Organisations such as the Arthritis Foundation of SA, 
a patient-orientated service, need to be established in other sub-
Saharan countries and patients informed about new developments 
relating to MSK disorders. The use of MRI and ultrasonography has 
to be encouraged and funds have to be invested to provide these 
services in state-owned medical facilities. The 21st century hails a 
new era in the management of MSK disorders and it is hoped that 
the GBD from MSK disorders will decrease as people live longer.
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